MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Meridian Bioscience Operating Expenses 2011-2026 | VIVO
Annual Operating Expenses Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 134 M | 108 M | 94.9 M | 81 M | 85.8 M | 80.8 M | 74.3 M | 65.8 M | 64.9 M | 63.7 M | 60.6 M | 59.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 134 M | 59.3 M | 81.1 M |
Quarterly Operating Expenses Meridian Bioscience
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59.6 M | - | - | 32.3 M | 28.9 M | - | 21.4 M | 23.6 M | 26.9 M | 66.3 M | 21.3 M | 26.9 M | 22.3 M | 62.3 M | 21.8 M | 22 M | 21 M | 74.1 M | 23.2 M | 21 M | 23.9 M | 65.1 M | 26.8 M | 23.7 M | 19 M | 55.6 M | 19.2 M | 19.4 M | 18 M | 49.3 M | 15.9 M | 18 M | 16.6 M | 48.4 M | 16.1 M | 16.6 M | 16.4 M | 46.1 M | 14.9 M | 16.4 M | 15.7 M | 44.3 M | 14.8 M | 15.7 M | 14.7 M | 44.6 M | 15.2 M | 14.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 74.1 M | 14.7 M | 28.9 M |
Operating Expenses of other stocks in the Diagnostics research industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
1.99 B | $ 111.16 | -2.04 % | $ 33.8 B |  USA |
 |
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
2.47 B | - | - | $ 19.8 B | USA |
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Sotera Health Company
SHC
|
309 M | $ 13.26 | -2.07 % | $ 3.77 B | USA |
 |
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M |  Israel |
|
Biodesix
BDSX
|
106 M | $ 14.28 | -2.19 % | $ 1.85 B | USA |
 |
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M |  Britain |
 |
BioNano Genomics
BNGO
|
41.3 M | $ 1.14 | -1.3 % | $ 6.21 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
726 M | $ 16.25 | -12.16 % | $ 175 M |  China |
 |
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
37.1 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Co-Diagnostics
CODX
|
45.3 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | China |
 |
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | USA |
 |
Castle Biosciences
CSTL
|
59.5 M | $ 24.03 | -2.71 % | $ 667 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
607 M | $ 158.22 | -4.18 % | $ 7.84 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 196.67 | -0.75 % | $ 21.8 B | USA |
 |
Organovo Holdings
ONVO
|
23.3 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
21.9 M | - | -16.95 % | $ 1.54 M | USA |
 |
DarioHealth Corp.
DRIO
|
49.3 M | $ 8.45 | - | $ 33.7 M | Israel |
 |
DexCom
DXCM
|
1.89 B | $ 62.38 | -5.61 % | $ 24.3 B | USA |
 |
Fulgent Genetics
FLGT
|
181 M | $ 15.72 | -4.06 % | $ 475 M | USA |
 |
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
226 M | $ 84.78 | -3.77 % | $ 10.6 B | USA |
 |
PerkinElmer
PKI
|
1.07 B | - | -0.91 % | $ 14.7 B | USA |
 |
Invitae Corporation
NVTA
|
343 M | - | - | $ 21.2 M | USA |
 |
ICON Public Limited Company
ICLR
|
408 M | $ 102.7 | -0.37 % | $ 8.47 B |  Irlanda |
 |
Illumina
ILMN
|
3.69 B | $ 118.42 | -4.81 % | $ 18.8 B | USA |
 |
Interpace Biosciences
IDXG
|
21.8 M | $ 1.68 | -2.89 % | $ 7.37 M | USA |
 |
IQVIA Holdings
IQV
|
2.94 B | $ 165.13 | -2.52 % | $ 28.4 B | USA |
 |
Lantheus Holdings
LNTH
|
123 M | $ 74.66 | -2.23 % | $ 5.04 B | USA |
 |
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K | Israel |
 |
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B |  Niderland |
 |
Medpace Holdings
MEDP
|
118 M | $ 455.39 | -2.4 % | $ 13.1 B | USA |
 |
Mettler-Toledo International
MTD
|
1.01 B | $ 1 240.08 | -2.36 % | $ 25.6 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
964 M | $ 4.43 | -4.22 % | $ 410 M | USA |
 |
ENDRA Life Sciences
NDRA
|
10.8 M | $ 4.7 | 2.4 % | $ 2.52 M | USA |
 |
NeoGenomics
NEO
|
430 M | $ 7.55 | -2.77 % | $ 967 M | USA |
 |
Neogen Corporation
NEOG
|
1.48 B | $ 8.85 | -3.33 % | $ 1.92 B | USA |
 |
National Research Corporation
NRC
|
38.5 M | $ 17.23 | -0.78 % | $ 386 M | USA |
 |
Celcuity
CELC
|
172 M | $ 108.87 | -5.06 % | $ 5.09 B | USA |
 |
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | USA |